In turn, this could slow disease progression
Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management
Clinical trials demonstrate that discontinuation of semaglutide typically results in gradual weight regain, with patients recovering approximately two-thirds of lost weight within one year of stopping treatment, according to STEP trial extension data
Versus a reputable research vendor that publishes independent third-party COAs (Janoshik or equivalent), the upgrade is narrower primarily chain-of-custody, sterility on the finished vial, and clinical supervision rather than the molecule itself
Ideal for jumpstarting weight loss, especially when combined with lifestyle changes